School of Computing, Australian National University, Acton, ACT 2601, Australia.
School of Computing, Australian National University, Acton, ACT 2601, Australia; Department of Computing, University of Turku, Turku, Finland.
J Biomed Inform. 2023 May;141:104365. doi: 10.1016/j.jbi.2023.104365. Epub 2023 Apr 14.
Ovarian cancer is a significant health issue with lasting impacts on the community. Despite recent advances in surgical, chemotherapeutic and radiotherapeutic interventions, they have had only marginal impacts due to an inability to identify biomarkers at an early stage. Biomarker discovery is challenging, yet essential for improving drug discovery and clinical care. Machine learning (ML) techniques are invaluable for recognising complex patterns in biomarkers compared to conventional methods, yet they can lack physical insights into diagnosis. eXplainable Artificial Intelligence (XAI) is capable of providing deeper insights into the decision-making of complex ML algorithms increasing their applicability. We aim to introduce best practice for combining ML and XAI techniques for biomarker validation tasks.
We focused on classification tasks and a game theoretic approach based on Shapley values to build and evaluate models and visualise results. We described the workflow and apply the pipeline in a case study using the CDAS PLCO Ovarian Biomarkers dataset to demonstrate the potential for accuracy and utility.
The case study results demonstrate the efficacy of the ML pipeline, its consistency, and advantages compared to conventional statistical approaches.
The resulting guidelines provide a general framework for practical application of XAI in medical research that can inform clinicians and validate and explain cancer biomarkers.
卵巢癌是一个严重的公共健康问题,对社区造成持久影响。尽管最近在手术、化疗和放疗干预方面取得了进展,但由于无法在早期识别生物标志物,这些进展的影响微乎其微。生物标志物的发现具有挑战性,但对于改善药物发现和临床护理至关重要。与传统方法相比,机器学习 (ML) 技术在识别生物标志物中的复杂模式方面具有无可估量的价值,但它们可能缺乏对诊断的物理洞察力。可解释的人工智能 (XAI) 能够更深入地了解复杂 ML 算法的决策过程,从而提高其适用性。我们旨在介绍结合 ML 和 XAI 技术进行生物标志物验证任务的最佳实践。
我们专注于分类任务和基于 Shapley 值的博弈论方法来构建和评估模型并可视化结果。我们描述了工作流程,并在使用 CDAS PLCO 卵巢生物标志物数据集的案例研究中应用了该管道,以展示其在准确性和实用性方面的潜力。
案例研究结果证明了 ML 管道的有效性、一致性和与传统统计方法相比的优势。
得出的准则为医学研究中 XAI 的实际应用提供了一个通用框架,可为临床医生提供信息,并验证和解释癌症生物标志物。